Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Colin Baigent,Lisa Blackwell,Rory Collins,Jonathan Emberson,Jon Godwin,Richard Peto,Julie E. Buring,Charles H. Hennekens,Patricia M. Kearney,Tom W. Meade,Carlo Patrono,Maria Carla Roncaglioni,Alberto Zanchetti +12 more
Reads0
Chats0
TLDR
In primary prevention without previous disease, aspirin is of uncertain net value as the reduction in occlusive events needs to be weighed against any increase in major bleeds.About:
This article is published in The Lancet.The article was published on 2009-05-30 and is currently open access. It has received 2954 citations till now. The article focuses on the topics: Stroke & Aspirin.read more
Citations
More filters
Journal ArticleDOI
Atherothrombosis and the role of antiplatelet therapy
TL;DR: The evidence for the routine use of aspirin or any other antiplatelet agent is mixed and suggests this should only be considered on an individual basis in high‐risk groups where the thrombotic risk outweighs the risk of major bleeding complications.
Journal ArticleDOI
On the importance of global cardiovascular risk assessment in people with type 2 diabetes.
TL;DR: This narrative review examines the concept of diabetes as a cardiovascular disease (CVD) risk equivalent, the rationale and approaches to absolute CVD risk estimation in type 2 diabetes, and the impact of their uptake on clinical decision making and the outcome of care assessed.
Journal ArticleDOI
Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add?
Keith A.A. Fox,John W. Eikelboom,Sonia S. Anand,Deepak L. Bhatt,Jackie Bosch,Stuart J. Connolly,Robert A. Harrington,Phillippe Gabriel Steg,Salim Yusuf +8 more
TL;DR: This poster presents a poster presented at the 2015 American College of Cardiovascular Disease Prevention and Research Conference (ACDRC) to present a poster titled “Advances in Cardiovascular Biology and Medicine: Foundations of Cardiac Rhythm Management and Vascular Integrity.”
Journal ArticleDOI
Bleeding risk of endoscopic ultrasound-guided fine-needle aspiration in patients undergoing antithrombotic therapy.
Tadahisa Inoue,Fumihiro Okumura,Hitoshi Sano,Yuji Kobayashi,Norimitsu Ishii,Yuta Suzuki,Shigeki Fukusada,Kenta Kachi,Takanori Ozeki,Kaiki Anbe,Hiroyasu Iwasaki,Takashi Mizushima,Kiyoaki Ito,Masashi Yoneda +13 more
TL;DR: Patients receiving antithrombotic treatment with endoscopic ultrasound‐guided fine‐needle aspiration are assessed for bleeding event rate associated with EUS‐FNA in order to assess the bleeding risk for patients treated with antithROMbotic agents.
Journal ArticleDOI
Contemporary Patterns of Discharge Aspirin Dosing After Acute Myocardial Infarction in the United States Results From the National Cardiovascular Data Registry (NCDR)
Hurst M. Hall,James A. de Lemos,Jonathan R. Enriquez,Darren K. McGuire,S. Andrew Peng,Karen P. Alexander,Matthew T. Roe,Nihar R. Desai,Stephen D. Wiviott,Sandeep R Das +9 more
TL;DR: Although aspirin dosing after percutaneous coronary intervention largely reflected prevailing guidelines before 2012, high-dose aspirin was prescribed with similar frequency in medically managed patients and to those in categories expected to be at high risk for bleeding.
References
More filters
Journal ArticleDOI
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
Colin Baigent,Anthony C Keech,Patricia M. Kearney,L Blackwell,Georgina Buck,Christine Pollicino,Adrienne Kirby,T Sourjina,Richard Peto,Rory Collins,R. J. Simes +10 more
TL;DR: Statin therapy can safely reduce the 5-year incidence of major coronary events, coronary revascularisation, and stroke by about one fifth per mmol/L reduction in LDL cholesterol, largely irrespective of the initial lipid profile or other presenting characteristics.
Journal ArticleDOI
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
TL;DR: Aspirin (or another oral antiplatelet drug) is protective in most types of patient at increased risk of occlusive vascular events, including those with an acute myocardial infarction or ischaemic stroke, unstable or stable angina, previous myocardian infarctions, stroke or cerebral ischaemia, peripheral arterial disease, or atrial fibrillation.
Journal ArticleDOI
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial
Lennart Hansson,Alberto Zanchetti,S. George Carruthers,Björn Dahlöf,Dag Elmfeldt,Stevo Julius,Joël Ménard,Karl Heinz Rahn,Hans Wedel,Sten Westerling +9 more
TL;DR: Intensive lowering of blood pressure in patients with hypertension was associated with a low rate of cardiovascular events and the potential benefit of a low dose of acetylsalicylic acid in the treatment of hypertension was assessed.
Journal ArticleDOI
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
Paul M. Ridker,Eleanor Danielson,Jacques Genest,Antonio M. Gotto,Wolfgang Koenig,Peter Libby,Alberto J. Lorenzatti,Jean G. MacFadyen,Børge G. Nordestgaard,James Shepherd,James T. Willerson,Robert J. Glynn +11 more
TL;DR: In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events.
Journal ArticleDOI
Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies
Gary Whitlock,Sarah Lewington,Paul Sherliker,Robert Clarke,Jonathan Emberson,Jim Halsey,Nawab Qizilbash,Rory Collins,Richard Peto +8 more
TL;DR: Below the range 22.5-25 kg/m(2), BMI was associated inversely with overall mortality, mainly because of strong inverse associations with respiratory disease and lung cancer, despite cigarette consumption per smoker varying little with BMI.